Yang Q - Search Results

1

Chemokine Receptor 4-Targeted PET/CT with [⁶⁸Ga]pentixather in Newly Diagnosed Multiple Myeloma: a Comparative Study with [⁶⁸Ga]pentixafor PET/CT.

Yang Q, Zhang F, Hao Z, Zhuang J, Huo L. Yang Q, et al. Mol Imaging Biol. 2024 Dec;26(6):986-994. doi: 10.1007/s11307-024-01953-7. Epub 2024 Sep 20. Mol Imaging Biol. 2024. PMID: 39304574

2

Chemokine Receptor 4-Targeted PET/CT With 68 Ga-Pentixather Detects More Lesions Than 68 Ga-Pentixafor PET/CT in Multiple Myeloma.

Yang Q, Zhang F, Hao Z, Zhuang J, Huo L. Yang Q, et al. Clin Nucl Med. 2024 Jun 1;49(6):592-593. doi: 10.1097/RLU.0000000000005194. Epub 2024 Apr 17. Clin Nucl Med. 2024. PMID: 38630995

3

Abdominal Metastases of Intracranial Germ Cell Tumor Via Ventriculoperitoneal Shunt Detected by 18F-FDG PET/CT.

Yang Q, Zhu W, Huo L. Yang Q, et al. Clin Nucl Med. 2020 Oct;45(10):836-837. doi: 10.1097/RLU.0000000000003235. Clin Nucl Med. 2020. PMID: 32804759

4

Biodistribution and radiation dosimetry of D-isomer of 4-borono-2-[¹⁸F]fluoro-phenylalanine: A comparative PET/CT study with L-isomer in healthy human volunteers.

Yang Q, Zhu W, Ren C, Ji H, Wang D, Liu Y, Li F, Du Y, Liu Y, Huo L. Yang Q, et al. Nucl Med Biol. 2021 Mar-Apr;94-95:32-37. doi: 10.1016/j.nucmedbio.2020.12.006. Epub 2021 Jan 8. Nucl Med Biol. 2021. PMID: 33486437

5

A prospective randomized, double-blind study to evaluate the diagnostic efficacy of ⁶⁸Ga-NODAGA-LM3 and ⁶⁸Ga-DOTA-LM3 in patients with well-differentiated neuroendocrine tumors: compared with ⁶⁸Ga-DOTATATE.

Zhu W, Jia R, Yang Q, Cheng Y, Zhao H, Bai C, Xu J, Yao S, Huo L. Zhu W, et al. Among authors: yang q. Eur J Nucl Med Mol Imaging. 2022 Apr;49(5):1613-1622. doi: 10.1007/s00259-021-05512-y. Epub 2021 Dec 7. Eur J Nucl Med Mol Imaging. 2022. PMID: 34874478 Clinical Trial.

6

Increased 68Ga-FAPI Uptake of Symptomatic Intracranial Atherosclerotic Plaque Revealed by PET/MR.

Yang Q, Zhang Z, Li M, Xu WH, Huo L. Yang Q, et al. Clin Nucl Med. 2022 May 1;47(5):469-470. doi: 10.1097/RLU.0000000000004050. Clin Nucl Med. 2022. PMID: 35025803

7

Performance of ⁶⁸Ga-Labeled Fibroblast Activation Protein Inhibitor PET/CT in Evaluation of Erdheim-Chester Disease: A Comparison with ¹⁸F-FDG PET/CT.

Ma J, Yang Q, Huo L, Dai J, Niu N, Cao X. Ma J, et al. Among authors: yang q. J Nucl Med. 2023 Sep;64(9):1385-1391. doi: 10.2967/jnumed.123.265691. Epub 2023 Jul 20. J Nucl Med. 2023. PMID: 37474266 Free article.

8

Comparison of Baseline ⁶⁸Ga-FAPI and ¹⁸F-FDG PET/CT for Prediction of Response and Clinical Outcome in Patients with Unresectable Hepatocellular Carcinoma Treated with PD-1 Inhibitor and Lenvatinib.

Wu M, Wang Y, Yang Q, Wang X, Yang X, Xing H, Sang X, Li X, Zhao H, Huo L. Wu M, et al. Among authors: yang q, yang x. J Nucl Med. 2023 Oct;64(10):1532-1539. doi: 10.2967/jnumed.123.265712. Epub 2023 Jul 27. J Nucl Med. 2023. PMID: 37500263 Free article.

9

Baseline [¹⁸F]FDG PET/CT may predict the outcome of newly diagnosed follicular lymphoma in patients managed with initial "watch-and-wait" approach.

Yang Q, Luo Y, Zhang Y, Zhang W, Zhou D, Li F. Yang Q, et al. Eur Radiol. 2022 Aug;32(8):5568-5576. doi: 10.1007/s00330-022-08624-7. Epub 2022 Mar 22. Eur Radiol. 2022. PMID: 35316362

10

Baseline ¹⁸F-FDG PET/CT may contribute to the determination of initial treatment strategy for newly diagnosed follicular lymphoma.

Yang Q, Zhang H, Zhang Y, Zhang W, Zhou D, Luo Y. Yang Q, et al. Eur J Radiol. 2024 Sep;178:111632. doi: 10.1016/j.ejrad.2024.111632. Epub 2024 Jul 15. Eur J Radiol. 2024. PMID: 39059082

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

25,718 results

Search Page

Filters